NKTR stock is up around 150% in today’s trading session following the recently announced positive results from its Phase 2b ...

Nektar Therapeutics said on Tuesday its lead drug candidate met the main goal of a mid-stage study testing the drug in eczema patients, sending its shares up by nearly 140%. In the 393-patient global ...

Nektar’s shares have surged more than twofold after a Phase IIb study of its atopic dermatitis (AD) therapy rezpegaldesleukin ...

Breakthrough study could lead to new treatments as experts explore how skin fungi trigger debilitating skin condition ...

Nektar Therapeutics shares doubled in early trading Tuesday after the U.S. biotech firm said it reached its targets in a ...

Nektar Therapeutics (NKTR) saw its stock surge 86% Tuesday morning after reporting strong midstage trial results for its ...

Nektar Therapeutics stock launched Tuesday after the biotech company hit every goal in a midstage study of its eczema ...

The Food and Drug Administration in February granted fast track designation for rezpegaldesleukin to treat adults and pediatric patients 12 years and up with moderate to severe atopic dermatitis, the ...

A team of researchers led by the University of Exeter have been awarded a £3.3 million grant by the Medical Research Council to study the treatment and potential cure for eczema.

Reuters, the news and media division of Thomson Reuters, is the world’s largest multimedia news provider, reaching billions of people worldwide every day. Reuters provides business, financial, ...

Shea butter has historically been used for skin ailments for centuries. Learn the wide range of shea butter benefits and how ...

Eczema is a complex condition. Your genes, immune system, and what touches your skin may play a role in eczema. (8) A board-certified dermatologist can determine what’s affecting your eczema and ...